Overview
BiotechPhase 3psilocybinHiring
Developing COMP360 synthetic psilocybin therapy for treatment-resistant depression. Currently in Phase 3 trials with Breakthrough Therapy designation from FDA. Headquartered in London with offices in New York.
Visit WebsiteLondon, UK
8
Clinical Trials
2016
Founded
150
Employees
80
Open Roles
Open Positions(80)
Research Areas
Clinical Pipeline(8)
Recruiting·Phase 2·psilocybin
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMP360 psilocybinPTSD - Post Traumatic Stress Disorder
Completed·Phase 2·psilocybin
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
PsilocybinPost Traumatic Stress Disorder
Completed·Phase 2·psilocybin
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
PsilocybinAnorexia Nervosa
Completed·Phase 2·psilocybin
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
PsilocybinTreatment Resistant Depression
Active, Not Recruiting·Phase 3·psilocybin
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
PsilocybinTreatment Resistant Depression
Completed·Phase 2·psilocybin
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
PsilocybinTreatment Resistant Depression
Completed·Phase 3·psilocybin
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
PsilocybinTreatment Resistant Depression
Active, Not Recruiting·Phase 2·psilocybin
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
PsilocybinMajor Depressive Disorder